These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 10357577)

  • 1. Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
    Stone GW
    Am J Cardiol; 1999 May; 83(9A):16E-20E. PubMed ID: 10357577
    [No Abstract]   [Full Text] [Related]  

  • 2. Low molecular weight heparins in the cardiac catheterization laboratory.
    Montalescot G; Cohen M
    J Thromb Thrombolysis; 1999 Jun; 7(3):319-23. PubMed ID: 10373715
    [No Abstract]   [Full Text] [Related]  

  • 3. Results from late-breaking clinical trials sessions at ACCIS '99 and ACC '99. American College of Cardiology.
    Morris DC
    J Am Coll Cardiol; 1999 Jul; 34(1):1-8. PubMed ID: 10399983
    [No Abstract]   [Full Text] [Related]  

  • 4. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty.
    Garbarz E; Farah B; Vuillemenot A; André F; Angioï M; Machecourt J; Bassand JP; Wolf JE; Danchin N; Prendergast B; Iung B; Vahanian A
    Am J Cardiol; 1998 Sep; 82(6):800-3, A9. PubMed ID: 9761094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abciximab in the treatment of ST-segment elevation myocardial infarction.
    Tan DS; Sim DK; Chan ES; Tan RS
    JAMA; 2005 Oct; 294(14):1760-1; author reply 1761. PubMed ID: 16219877
    [No Abstract]   [Full Text] [Related]  

  • 7. Guidelines for acute coronary syndrome without ST elevation.
    Toquero Ramos J; Silva Melchor L; Jiménez Mazuecos J; Ortigosa Aso J
    Lancet; 2002 Apr; 359(9314):1349; author reply 1350. PubMed ID: 11965311
    [No Abstract]   [Full Text] [Related]  

  • 8. The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade.
    Roe MT; Moliterno DJ
    Cleve Clin J Med; 1998 May; 65(5):267-72. PubMed ID: 9599910
    [No Abstract]   [Full Text] [Related]  

  • 9. On the use of abciximab in percutaneous coronary intervention.
    Iversen AZ
    Dan Med Bull; 2011 Aug; 58(8):B4312. PubMed ID: 21827726
    [No Abstract]   [Full Text] [Related]  

  • 10. Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.
    Brener SJ
    Cleve Clin J Med; 2000 Jan; 67(1):59-65. PubMed ID: 10645678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials.
    van de Werf F
    Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200
    [No Abstract]   [Full Text] [Related]  

  • 13. Stents are the CADILLAC of care. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications.
    SoRelle R
    Circulation; 2002 Apr; 105(14):e9094-5. PubMed ID: 11942340
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antithrombotics and interventional cardiology].
    Collet JP; Montalescot G
    Arch Mal Coeur Vaiss; 1999 Nov; 92(11 Suppl):1667-79. PubMed ID: 10598250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monoclonal antibodies in cardiology].
    Legrand V
    Rev Med Liege; 2009; 64(5-6):310-2. PubMed ID: 19642465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
    Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
    Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
    [No Abstract]   [Full Text] [Related]  

  • 19. Percutaneous revascularization for unstable angina in the elderly.
    Hirsch H; Lazar J; Marzo KP; Steingart RM
    Coron Artery Dis; 2000 Jun; 11(4):315-22. PubMed ID: 10860174
    [No Abstract]   [Full Text] [Related]  

  • 20. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.